NPM1 and acute lymphoblastic leukemia: Another phase I/II trial (NCT06052813) using BMF-219 recruiting patients R/R KMT2Ar or NPM1-m AML and MPAL/ALL with KMT2Ar is estimated to be completed by 2027.